ADI is pleased to announce that abstract submissions for the upcoming Global Conference of ADI in 2026 are now open! Submit an abstract to showcase your work or research at this international event: bit.ly/4dF5nPr

#ADI2026 #GlobalConferenceOfADI #Lyon #DementiaConference #Dementia

ADI’s newest report, From Plan to Impact report 2025 is NOW AVAILABLE for download on our website! Access the report: bit.ly/3ElAgez

#Dementia #DementiaPolicy #WorldHealthAssembly #WHO #WorldHealthOrganization #WHA78 #FromPlanToImpact

Learn more about the ongoing debate on the regulatory process for the new treatments for #Alzheimer ’s disease in #Europe: www.thelancet.com/journals/lan...

#AlzheimersTreatment #Lequembi #Donanemab #AmyloidTreatment #Lecanemab

This year, World Health Assembly is convening for its 78th meeting, a meeting that will include a crucial decision on whether to extend the WHO Global Action Plan on the public health response to dementia.
Register for our upcoming From Plan To Impact report launch: bit.ly/4iLrLYV
#Dementia

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended against granting the marketing authorisation of #donanemab ( #Kisunla ) in the treatment of the mild dementia stage of Alzheimer’s disease across the EU and EEA.
www.ema.europa.eu/en/medicines...